Back to News
research

Anthropic buys biotech startup Coefficient Bio in $400M deal: Reports

Dominic-Madori Davis
Loading...
2 min read
0 likes
⚡ Quantum Brief
Anthropic acquired stealth biotech AI startup Coefficient Bio in a $400 million all-stock deal, per reports from The Information and Eric Newcomer. The acquisition aligns with Anthropic’s expanding focus on healthcare and life sciences. The deal follows Anthropic’s October 2025 launch of Claude for Life Sciences, an AI tool designed to accelerate scientific research. Coefficient Bio’s expertise in AI-driven drug discovery complements this initiative. Coefficient Bio was founded just eight months ago by Samuel Stanton and Nathan C. Frey, former Genentech computational drug discovery specialists. The startup aimed to streamline biological research using AI. The 10-person Coefficient Bio team will join Anthropic’s health and life science division, bolstering its capabilities in computational biology and drug development. Sources confirmed the deal’s closure but declined to disclose financial details. The acquisition underscores Anthropic’s strategic push into AI-powered biotech innovation.
AI Audio Summary
0:00 / 0:00
Click to play
AdobeStock_1623156856_Preview.jpeg
Quantum News · Media Library

In Brief Posted: 1:28 PM PDT · April 3, 2026 Image Credits:Krisztian Bocsi/Bloomberg / Getty Images Dominic-Madori Davis Anthropic buys biotech startup Coefficient Bio in $400M deal: Reports Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The Information and Eric Newcomer. Sources close to the deal confirmed to TechCrunch that it closed, though declined to comment on the amount. The deal comes as Anthropic continues its push into healthcare and life sciences, following its October announcement of Claude for Life Sciences, a tool that aims to help scientific researchers make discoveries. Coefficient Bio’s founders, Samuel Stanton and Nathan C. Frey, launched the startup eight months ago, having both worked in computational drug discovery at Genentech’s Prescient Design. Coefficient Bio was using AI to help make drug discovery and other forms of biological research more efficient.

The team, consisting of around 10 people, is expected to join Anthropic’s health and life science team. Topics AI, Biotech & Health, Claude, In Brief, Mergers and Acquisitions, Privacy, Startups, Venture April 30 San Francisco, CA StrictlyVC kicks off the year in SF. Get in the room for unfiltered fireside chats with industry leaders, insider VC insights, and high-value connections that actually move the needle. Tickets are limited. REGISTER NOW Newsletters See More Subscribe for the industry’s biggest tech news TechCrunch Daily News Every weekday and Sunday, you can get the best of TechCrunch’s coverage. TechCrunch Mobility TechCrunch Mobility is your destination for transportation news and insight.

Startups Weekly Startups are the core of TechCrunch, so get our best coverage delivered weekly. StrictlyVC Provides movers and shakers with the info they need to start their day. No newsletters selected. Subscribe By submitting your email, you agree to our Terms and Privacy Notice. Latest in Venture In Brief Anthropic buys biotech startup Coefficient Bio in $400M deal: Reports Dominic-Madori Davis 2 hours ago In Brief Gateway Capital announces first close of $25M Fund II Dominic-Madori Davis 1 day ago Startups Diverse teams start with diverse VCs, with Leah Solivan, Taskrabbit Maggie Nye Isabelle Johannessen 1 day ago

Read Original

Tags

drug-discovery
quantum-investment
startup
partnership

Source Information

Source: TechCrunch

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.